【摘要】 目的 評價腎移植術后他克莫司（TAC）低劑量對比常規劑量干預的療效和安全性。 方法 檢索MEDLINE、EMbase、SCI、CBM、Cochrane圖書館，納入腎移植術后TAC低劑量對比常規劑量免疫抑制治療的隨機對照試驗（RCT）。檢索時間從各個數據庫建庫至2009年12月，對納入研究進行方法學質量評價和Meta分析。 結果 納入3個RCT，其中A級研究2個，B級研究1個。分析結果顯示:兩組急性排斥反應發生率比較，無統計學意義[RR=1.39， 95%CI(0.64， 3.01)]；腎小球濾過率、受者/移植物生存率和納入分析的安全性指標差異均無統計學意義。 結論 基于當前臨床證據，腎移植術后TAC低劑量與常規劑量干預相比，近期療效和安全性相似；遠期結果尚需進一步研究探討。【Abstract】 Objective To evaluate the effect and safety of low-dose versus standard-dose tacrolimus immunosuppressive therapy on kidney transplant recipients. Methods MEDLINE, EMbase, SCI, CBM and the Cochrane library were searched and randomized controlled trials (RCT) of low-dose versus standard-dose tacrolimus immunosuppressive therapy in kidney transplant recipients were gathered. The search was updated in December 2009. Quality assessment and meta-analysis were performed. Results A total of three RCT were identified, two of which were graded A and one was graded B. The analysis results indicated that RR (95%CI) value of the acute rejection rate was 1.39 (0.64, 3.01); glomerular filtration rate, patient/graft survival rate, and safety analysis were not significant different between the two groups. Conclusion Based on the evidence currently, compared to standard-dose TAC, Low-dose TAC has the same effect and safety results, but further study are needed to get the long term results.